Professor Nikolaos (Nikos) PapadopoulosPresident
He has extensive clinical and educational experience in paediatric allergy, having headed for many years a unit caring for more than 7,000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians and allergists.
His research focus is the interface between infection and allergic disease, with an emphasis on asthma exacerbations and food allergy. He is the Coordinator of the EU-funded CURE project. He has extensive collaborations in the context of EU projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST.
Prof. Papadopoulos has published over 300 papers (h-index: 70), has received several international awards and is invited to speak at international scientific meetings some 30 times a year. Moreover, he has served or is serving on the boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013–2015 President of EAACI and is currently the President of the Respiratory Effectiveness Group (REG).
Walter G CanonicaVice President for Global Collaboration
Allergist and Pulmonologist
Giorgio Walter is Professor of Respiratory Medicine at Humanitas University & Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital-Milano Italy Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.
Professor Sinthia Bosnic-AnticevichVice President for Communications
Professor Sinthia Bosnic-Anticevich is an internationally recognised leader in in the field of respiratory medicines. She is the founder and Team Leader of the Quality Use of Respiratory Medicines Group, located at the Woolcock Institute, University of Sydney and Sydney Local Health District. The group focuses on generating new knowledge about the use of respiratory medicines from the patient, health care provider and societal perspective with output of over 120 research publications in the area. The research of Professor Bosnic-Anticevich and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines. Her research has been critical to our understanding of the role of respiratory medication use in the precision medicine approach to respiratory disease management. Professor Bosnic-Anticevich works across the continuum of the health care settings, with a multidimensional and inter-professional approach to better understand and improving health outcomes for patients using respiratory medicines.
She is on the executive of ARIA (Allergic Rhinitis in Asthma) and chair of Pharmacy ARIA, which is the leading global initiative for the management of Allergic Rhinitis in pharmacy. Sinthia Bosnic-Anticevich’s role as Chair of this group is to lead the development of the Pharmacy ARIA guidelines and to work with international experts in the field to develop guidelines for pharmacy that can integrate the practice of pharmacy across the health disciplines. The latest Pharmacy ARIA guidelines are currently under review.
Professor Bosnic-Anticevich is Vice President of the Respiratory Effectiveness Group (REG), an investigator-led, not-for-profit research initiative that has been set up in recognition of the potential value of real-life research and the need to harness real-life evidence to inform meaningful practice guidelines, drug licensing and prescribing decisions. In this capacity she provides international leadership in setting research standards and excellence in real-life research and in evaluating mechanisms for integrating real-life research into clinical guidelines and practice. Currently there are over 300 researchers within the REG network.
Nicolas RocheVice President for Methodology
Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes, France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is a member of the GOLD science committee, President of Société de Pneumologie de Langue Française, co-chair of the 2018 ERS Congress and member of the American Thoracic Society. He is guidelines director of the ERS and member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council, vice-president of the Respiratory Effectiveness Group and member of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national projects on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.
Professor Antonio AnzuetoVice President for Internal Organisation
Antonio Anzueto is Professor of Medicine at the University of Texas Health Science Center and Chief of the Pulmonary Section for the South Texas Veterans Health Care System, San Antonio, Texas, USA. In addition, he is a faculty member of the Pulmonary Disease and Critical Care Medicine Division, the Medical Director for the Pulmonary Function Laboratory at the University Hospital in San Antonio, and an adjunct scientist at the Southwest Foundation for Biomedical Research, San Antonio, Texas.
His areas of interest include chronic obstructive pulmonary disease, chronic bronchitis, community-acquired pneumonia, sepsis, acute respiratory distress syndrome, and lung transplantation.
He is a member of a number of medical committees, a reviewer for various scientific journals including the New England Journal of Medicine, and has published over 250 manuscripts in highly rated medical journals. He has extensive research experience as has been the principal investigator of numerous large multicenter clinical trials. He is member of several international committees such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD); ATS/IDSA Community Acquired Pneumonia Guidelines Committee; International committee – consensus conference on ALI/ARDS. He is also a practicing physician that has been nominated over the last 8 years as a “Best Pulmonary Doctor” in San Antonio, Texas.
Alan KaplanVice President for Events
MD CCFP(EM) FCFP
Family Physician practicing in York Region, Ontario, Canada.
Chairperson of the Family Physician Airways Group of Canada (www.fpagc.com)
Past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada
Senate member of the International Primary Care Respiratory Group
President of the IPCRG 5th biennual world scientific meeting, “Making Every Breath Count” Toronto June 2-5, 2010
Chair of the Council of Organizing Members of the Canadian Network for Respiratory Care.
Member of Past Canadian Consensus Guidelines for H pylori, Asthma, COPD and Sinusitis
Representative of the College of Family Physicians of Canada to the SARS clinical working group.
Member of Chronic Respiratory Disease Surveillance Advisory Committee (Public Health Agency of Canada)
Member of the Health Canada Section on Allergy and Respiratory Therapies
Member of the Canadian Metropolitan Tuberculosis Subcommittee
Co-Chair, Health Quality Ontario COPD Community Management standards committee
Board member, Thrombosis Canada
Vice President, Respiratory Effectiveness Group
International editor for Nature’s Primary Care Respiratory Journal
International editor for the Italian Journal of Primary Care
Non-respiratory medical interests:
Community Pain consultant
Palliative Care community physician
Hospitalist, Brampton Civic Hospital
Married with four children and four dogs
Ardent baseball player
Dermot RyanVice President for Finances and Supporter Relationships
Dermot Ryan is a recently retired GP who has had a long-term interest in Respiratory and Allergic diseases with regard to primary care. He was previously chair of Primary Care Society during which time he was instrumental in establishing the professorial post of Professor in Primary Care Respiratory Medicine, the first ever clinical discipline to be established in any academic department of primary care. During this time, he was involved in the set-up of what is now npj Primary Care Respiratory Medicine. The purpose of these two activities were to research real life solutions to the real-life problems encountered in daily practice and provide a vehicle for the dissemination of this research. He was previously the Clinical Respiratory lead of East Midland Strategic Health Authority. He was the first chair of the primary care interest group of EAACI where he served (and is still serving) on many task forces. He succeeded David Price as president of REG and in turn was succeeded by Nikos Papadopoulos. He is Honorary Clinical Research Fellow at the University of Edinburgh.
Dr. Chapman is Director of the Asthma and Airway Centre of the University Health Network, President of the Canadian Network for Respiratory Care and Director of the Canadian Registry for Alpha-1 Antitrypsin Deficiency.
A Professor of Medicine at the University of Toronto, Dr. Chapman is an internationally respected researcher and lecturer in the fields of asthma and COPD. With more that 16,000 citations to his published work, he is in the top 1% of cited medical researchers.
Adnan Custovic is Clinical Professor of Paediatric Allergy at Imperial College London. His professional training consisted of a Specialist training in Paediatrics (1987-91) and successive appointments as Clinical Research Fellow and Specialist Registrar in Allergy (University Hospital of South Manchester, 1992-98). This period saw him awarded M.Sc. (1991), M.D. with Gold Medal (1996) and Ph.D. (2000). He was promoted to a professorship at the University of Manchester in 2002, and moved to Imperial College in 2015.
In 2015 he was awarded a highly prestigious European Respiratory Society Gold Medal for research in asthma. In 2013 he received the BSACI William Frankland Medal for outstanding contributions to clinical allergy in the UK, and the CIPP President’s award for the distinguished achievements in childhood asthma. He delivered numerous prestigious keynote/named lectures, including Ann Woolcock lecture (2016), Nemacolin Asthma Conference keynote lecture (2014), Cas Motala Memorial Lecture (South African Allergy Society, 2013), James Hutchison's Memorial Lecture (Hong Kong Paediatric Society, 2012), the RSM Priscilla Piper Lecture (2011) and Caspar Weinberg Lecture (2007).
He currently serves as the Associate Editor of the American Journal of Respiratory and Critical Care Medicine, and on the International Advisory Board of the Lancet Child and Adolescent Health. He has served as a Secretary of the BSACI for two terms, and as President of Asthma section of the EAACI.
His research has focused upon the origins and natural history of asthma and allergy across the life-course, with an emphasis on prevention and translation for patient benefit. His research findings are of great practical significance, and have informed and changed national and international guidelines on asthma prevention/management. His studies in food allergy substantially impacted clinical practice. His discovery that IgE-response to peanut allergen Ara h 2 is much more predictive of true peanut allergy than standard tests using whole allergen extract marked the start of the component-resolved diagnostics as the new gold standard in clinical practice. His current research programme combines world-leading expertise in birth cohorts and statistical machine learning, and capitalises on the recent developments within the field of computer sciences to provide powerful new tools that are well suited to the challenge of integration of different scales of data (from molecular-level to population-level), and different levels of directness of measurement of factors.
He has supervised 17 PhD/MD students to completion.
Dr. Ducharme is Professor in the Departments of Paediatrics and of Social and Preventive Medicine, University of Montréal. She is a paediatrician and clinical epidemiologist in the Centre Hospitalier Universitaire Sainte-Justine. She concluded her term as co-chair of the Asthma Assembly of the Canadian Thoracic Society and remains involved in this assembly, responsible for generating asthma guidelines in Canada.
Dr Ducharme leads a productive career as physician caring for asthmatic children, as teacher, research mentor, and clinical scientist. Her research program, which has received uninterrupted research funding, focuses on improving paediatric asthma morbidity through development of clinical and research instruments specific to children, educational and drug interventions, systematic reviews, dissemination of evidence-based guidelines, and development of interventions to improve adherence to guidelines. Dr Ducharme is paediatric editor of the Cochrane Airways Review group since its birth in 1995. Her research program has led to over 170 publications, 190 invited talks, numerous research awards, and co-authorship for several adult and paediatric Canadian Asthma Consensus statements as well as on international statements, namely on lung function testing in preschool-aged children.
Dr. Ducharme’s research program focuses on the secondary and tertiary prevention in children with asthma, using various pharmacological and non-pharmacological approaches.
Dr. Kevin R. Flaherty is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine at the University of Michigan in Ann Arbor, Michigan. Dr. Flaherty is the director of the Interstitial Lung Disease program, serves as Vice-Chair of the Medical School Institutional Review Board for Human Subjects Research and is the steering committee chair for the pulmonary fibrosis foundation’s Care Center Network and Patient Registry. His clinical and research interests center around the diagnosis, monitoring, and care of patients with interstitial lung diseases. He has been and continues to be the principal investigator on numerous grants and clinical trials related to the study and treatment of patients with idiopathic interstitial pneumonias, particularly idiopathic pulmonary fibrosis.
Mark Jones is an Associate Professor in Respiratory Medicine at the University of Southampton, and Honorary Consultant Physician at University Hospital Southampton. His clinical interest is fibrotic interstitial lung diseases (ILDs) and this informs his research which is focused on identifying determinants of progressive lung fibrosis, its diagnosis and treatment. He received his medical degree with honours from the University of Southampton. Following an NIHR Academic Clinical Fellowship he was awarded a Wellcome Trust Clinical Research Training Fellowship investigating the pathogenetic role of collagen in idiopathic pulmonary fibrosis which led to the award of a PhD. As Academic ILD lead for the NIHR Southampton Biomedical Research Centre he established a longitudinal cohort of patients with ILD, together with the routine biobanking of samples from all patients undergoing surgical lung biopsy for the investigation of suspected interstitial lung disease. These resources support his research investigating determinants of progressive fibrotic lung diseases with the aims of developing novel approaches to disease classification, prognostic stratification, and treatment.
Rupert Jones is Professor of Respiratory Medicine at Observational and Pragmatic Research Institute, Singapore, and Associate Professor at the Faculty of Medicine and Dentistry, Plymouth University. Rupert co-director of the Makerere Lung Institute. He has been involved in COPD research, policy and education for more than 20 years. His policy including the National Outcomes Strategy for COPD, the National COPD Audit in Primary Care and pulmonary rehabilitation standards. His research interests are in severe asthma, COPD, post TB lung disease and pulmonary rehabilitation, including in Africa and other resource limited settings through the RECHARGE and FRESH AIR projects (www.plymouth.ac.uk/research/primarycare/fresh-air). He has published over 80 papers, 2 questionnaires including the Severe Asthma Questionnaire (www.SAQ.org.uk) and the Lung Information Needs Questionnaire (www.linq.org.uk) and several books.
Janwillem Kocks is a practicing General Practitioner, Professor of Inhalation Medicine at the Observational and Pragmatic Research Institute in Singapore and managing director of the General Practitioners Research Institute.
He obtained his medical degree in 2004 at the University of Groningen. In January 2005 he started his PhD research within the Groningen Research Institute on Asthma and COPD (GRIAC) resulting in his thesis “Towards health status guided care in COPD”. He combined his PhD training with the specialist training for general practitioner and graduated as general practitioner in March 2009.
He visited the Medical Research Institute of New Zealand (headed by Professor Richard Beasley) between July 2013 and February 2014 as senior research fellow and was visiting professor at the Observational & Pragmatic Research Institute (headed by Professor David Price) end of 2017.
He is president elect of the International Primary Care Respiratory Group (IPCRG), chair of the General Practice and Primary care Group of the European Respiratory Society (ERS).
His current research focuses on diagnosis and individualised management of both asthma and COPD in primary care including improving inhalation technique by education and smart inhalers.
Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).
MBChB, MD, MRCPCH
Clare Murray is a senior lecturer at The University of Manchester and a consultant in paediatric respiratory medicine at the Royal Manchester Children’s Hospital. Both her clinical and academic work centres on children with asthma and she leads the paediatric severe asthma service for the North West of England.
As a Senior Lecturer at the University of Manchester, she is part of the Division of Infection, Immunity and Respiratory Medicine. She joined the Manchester Asthma and Allergy Study (MAAS; a large birth cohort study set up in 1995 to investigate the development of asthma and allergic disease) in 1999 as a research fellow. Having completed her MD in “Environmental allergens and childhood asthma”, she developed a strong interest in the role of environmental factors, including allergens, viruses and diet, in the development of asthma and allergic disease. She continued to work closely on Manchester Asthma and Allergy Study and in 2015 became chief investigator of the study. Her other research interests include treatment options (both pharmacological and non-pharmacological) for asthma and severe asthma and diagnostic pathways for asthma.
Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the Respiratory Unit of the Department of Emergency Medicine, S. Anna University Hospital, Ferrara, Italy.
He trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer.
He has coordinated several pivotal studies in asthma and COPD, and has authored more than 300 articles in peer-reviewed journals.
Joan B Soriano
Associate Professor of Medicine, Universidad Autónoma de Madrid, Cátedra UAM-Linde, and Senior Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, Madrid, Spain
Joan B Soriano graduated in medicine in 1993 and received his PhD in epidemiology and methodology of biomedical research in 1996, both from the Universitat Autònoma de Barcelona. He completed his education in epidemiology with a Master of Science at the Erasmus University, Rotterdam, The Netherlands, and a post-doctoral stay at the Johns Hopkins School of Public Health, in Baltimore, USA. He worked in the pharmaceutical industry in the UK from 1998, and later in the USA from 2003. Then, in 2005 he moved back to CIMERA in Mallorca, Spain. He serves in the GesEPOC COPD guidelines, directed the SEPAR’s Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational medicine. Since 2007 he is an Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine. He has published over 270 papers and over 20 book chapters. In May 2011, he received the Josep Trueta Award for scientific and medical achievements, and in 2014 was appointed FCCP of Chest and Foundational Fellow of the ERS.
Steve qualified in medicine at the University of Newcastle-upon-Tyne in 1992 and trained in paediatrics in centres around the North East of England with extended spells in New Zealand and Australia. He is a clinical academic and has been a consultant paediatrician in Aberdeen for 15 years, working as a general paediatrician and a respiratory paediatrician. He became Professor at the University of Aberdeen in 2017 where his research interest are early origins of disease, monitoring asthma and analysing routinely acquired health care data. He currently holds more than £1 million in grants, has published more than 100 peer-reviewed papers, but is first and foremost a jobbing clinician.
Professor Peter Barnes DM
DSc, FRCP, Master FCCP, FMedSci, FRS, FERS
Peter Barnes is Margaret-Turner Warwick Professor of Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.
He qualified at Cambridge and Oxford Universities (first class honours) and was appointed to his present post in 1987 and was head of respiratory medicine at Imperial College until 2017. He has published >1200 peer-review papers on asthma, COPD and related topics (h-index 167) and has written or edited over 50 books. He is one of the top 10 most highly cited researchers in the world and the most highly cited respiratory researcher in the world over the last 30 years.
He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of global guidelines on COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest, Journal of COPD Foundation and Editor in Chief of Up-to-Date Pulmonary Diseases. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society, the Sadoul Lecture at the European Respiratory Society and the Croonian Lecture at the Royal College of Physicians. He has been received honorary degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland), Leuven (Belgium) and Maastricht (Netherlands). He is an emeritus NIHR Senior Investigator, a Master Fellow of the American College of Chest Physicians and elected member of Academia Europaea and American Association of Physicians. He served as President of the European Respiratory Society 2013/14 and is currently President of the British Association for Lung Research. He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Professor Doctor Moisés A. CALDERON MD PhDLondon, United Kingdom
Section of Allergy and Clinical Immunology, Imperial College London, Royal Brompton Hospital, London UK.
Professor Moisés A. Calderón is based at the Royal Brompton Hospital, Imperial College, National Heart and Lung Institute in London. In his current position as Director of the Clinical Trials Unit, Prof. Calderón is conducting clinical research investigating the efficacy and safety of allergen immunotherapy. In addition, he has participated as an independent allergy expert in various studies of allergen immunotherapy. Prof. Calderón acts with great clinical experience as a competent expert in safety committees and clinical investigations, focusing particularly on allergy sublingual immunotherapy tablets. He is an Executive Committee Member of the European Academy of Allergy and Clinical Immunology.
Prof. Calderón is the author of a long list of peer-reviewed publications in international journals on research topics in allergy – and continuously acts as a reviewer on scientific publications. He has participated as a key opinion leader on allergen immunotherapy at many international meetings.
Prof. Calderón was educated at the University of Costa Rica were he obtained an MD in Internal Medicine and at the University of London were he obtained his PhD in Allergy and Clinical Immunology. He joined Imperial College London and the Royal Brompton Hospital in 2002. Prof. Calderón has worked as an academic with the Cochrane Group at Oxford University. Prof. Calderón has been part of the Executive Working Group of the Global Alliance Against Chronic Respiratory Diseases (GARD) of the World Health Organization.
In addition to his clinical work and comprehensive clinical research activity Prof. Calderón is also involved with lecturing at major international courses and meetings covering the areas of asthma, basic clinical allergy, and allergen immunotherapy.
Professor Frederic de Blay
Frederic de Blay is pulmonologist and allergist at the University Hospital of Strasbourg and Professor of pulmonology at the faculty of Medicine at the Strasbourg University (France).
He is the head of the department of Chest Diseases at the University Hospital of Strasbourg.
Since several years, his research has been focused on respiratory allergy, and indoor, outdoor and occupational environments. He is currently working on new methods of nasal and bronchial challenge tests and on pathophysiology of occupational asthma and allergic rhinitis. An environmental chamber has been built inside the New University Hospital of Strasbourg close to the division of allergy since 2017.
He has created a new occupation called Medical Indoor Environment Counselor. They are 150 in France and in Belgium and in Switzerland. He has been involved in regulation of Name Patient Product at the French level and a paper was published on this topic.
He has been president of the French Society of Allergology from 2008-2010. He is currently President of the French Federation of Allergology.
He has been president of the 6.2 group “occupational and environment health” at the ERS from 2011 to 2014. He is the author of 220 international articles and book chapters.
He has been chairman of the Research Committee of the University Hospital of Strasbourg and the Research Committee of the North East part of France which composed 5 university hospitals (Besançon, Dijon, Reims, Nancy and Strasbourg) and 20 non-university hospitals.
Mark FitzgeraldMB, MD, FERS, FRCPI, FRCPC, FACCP, FACP
Dr. J. Mark FitzGerald graduated from University College Dublin in 1978. He completed post-graduate training in Respiratory Medicine and Clinical Epidemiology at McMaster University before accepting a position on Faculty at McMaster University in 1987. In 1989, he moved to the University of British Columbia.
Dr. FitzGerald is the director of the Centre for Heart and Lung Health He is a former Head of the Respiratory Medicine Divisions at both UBC and Vancouver General Hospital and co -Director of the UBC Institute for Heart and Lung Health. He practices at The lung Centre, Vancouver General Hospital.
Dr. FitzGerald is past Chair and an ongoing current member of both the GINA Science Committee and the GINA Executive. He is a past Chair and current member of the CTS Asthma Assembly. He is past President of the Canadian Thoracic Society. He has published over 500 peer reviewed papers and editorials
Dr Mina Gaga MD, PhD is the Director of the 7th Respiratory Medicine Dept and Asthma Centre at Athens Chest Hospital. She is much involved in clinical work focusing particularly in asthma and lung cancer, in clinical research and in medical education programs. She has been actively involved as PI in multiple clinical trials in Asthma and COPD, has been active internationally in guideline development for severe asthma and screening in lung cancer and has published extensively in these research areas. She has moreover served as Director of Learning Resources of the ERS School, Secretary of the European Board of Accreditation in Pneumology (EBAP), Secretary General and President of the ERS, serves in the HERMES examination committee and the European Αdult Respiratory Medicine HERMES Diplomas.
Professor Liam Heaney
Professor Liam Heaney is Professor of Respiratory Medicine at Queens University Belfast, N Ireland, who trained in Northern Ireland and the Royal Brompton Hospital in London. He is Director of the Northern Ireland Regional Difficult Asthma Service which over the past 10 years has developed a programme of optimal clinical assessment in this population including multi-disciplinary systematic assessment and identification and management of poor adherence. He has chaired the British Thoracic Society Specialist Advisory Group for Asthma, the Evidence Review Group for Difficult Asthma for the British Thoracic Society / Scottish Intercollegiate Guideline on Asthma Management and has been a member of the National Steering Committee for the UK Asthma Guidelines. He is a member of the Medical Research Council Population and Systems Medicine Board and Experimental Medicine Panel. He co ordinates the UK Severe Asthma Registry and NICE UK Thermoplasty Registry. He is Academic Lead the Medical Research Council UK Refractory Stratification Programme (http://www.rasp.org.uk) and has published extensively on the clinical assessment and management of difficult to control asthma in adults
Professor Chin Kook Rhee
Prof. Rhee currently serves as the Professor in the Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine at Seoul St. Mary’s Hospital of The Catholic University of Korea. Prof. Rhee is member of Editorial Board of American Journal of Respiratory and Critical Care Medicine, Journal of COPD, and Tuberculosis and Respiratory Diseases. Prof. Rhee is a Head Elect of APSR COPD assembly. He is also a member of APSR council, APSR Education Committee. He is a member of steering committee of International Severe Asthma Registry. He is also a member of many committee of Korean Academy of Tuberculosis and Respiratory Disease. He also serves on the Steering Committee of the Korean COPD Research Group, Korean Asthma Research Group, Korean Pulmonary Rehabilitation Group, Korean Obstructive Lung Disease (KOLD) Cohort, KOrea COPD Subgroup Study (KOCOSS) Cohort. Prof. Rhee has published 130 SCI(E) articles (55 publications as first/corresponding author). The focus of his research is COPD and asthma with primary interests in topics related to cohort study, big data analysis, ACO, and airway remodeling.
Andrew Menzies-Gow is the clinical lead of the severe asthma service and Director of the Lung Division at the Royal Brompton Hospital. He is a Professor of Practice (Respiratory) at Imperial College and his research interests include novel therapies for severe asthma and eosinophilic lung disease. He chaired the NICE Guideline Development Group for Asthma: Diagnosis and Monitoring and is a member of the Adult Respiratory Clinical Reference Group for NHS England leading on the commissioning of severe asthma services.
Luis Pérez de Llano
Dr Luis Pérez de Llano graduated in medicine in 1989 from Santiago’s University, Santiago de Compostela, Spain, and did postgraduate training in Respiratory Medicine at the Hospital Marques de Valdecilla (Santander, Spain). He went on to earn his Ph.D. in Medicine from the University of Cantabria, researching non-invasive ventilation in patients with obesity-hypoventilation syndrome.
Dr Pérez de Llano has been practicing as a pneumologist since 1996, the last 13 years in Lugo, at the Lucus Augusti Hospital as the head of the Pneumology Service. Pérez de Llano's practice specializes in the care of severe asthma patients and his interests also include end-of-life issues, chronic obstructive bronchial diseases and pulmonary embolism. Dr. Pérez de Llano has authored or co-authored several books and over 100 publications in peer reviewed journals and delivered over 450 professional presentations at regional, national and international conferences.
Dr Pérez de Llano holds currently the following positions:
-Head of the Pneumology Service at Lucus Augusti Universitary Hospital.
-Director of the Research Unit at Lucus Augusti Universitary Hospital.
-Member of the Health Research Institute of Santiado de Compostela (IDICHUS) board.
-Director of the Asthma Integrated Research Program of the Spanish Respiratory Society (SEPAR).
Professor David Price, FRCGPPrimary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK
Managing Director of Observational and Pragmatic Research Institute, Singapore
Managing Director of Optimum Patient Care, Australia and UK
Professor David Price is head of The Observational & Pragmatic Research Institute (Singapore) and Optimum Patient Care (Australia and UK), and is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). His area of interest lies in real life respiratory and allergy research. To date he has authored over 490 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. In addition he established the Optimum Patient Care Research Database (OPCRD; http://opcrd.co.uk) with over 6.3 million patients, and the first International Severe Asthma Registry (ISAR; http://isaregistries.org/) with over 20 countries collaborating. He is currently Editor-in-Chief of Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.
Carmen Vidal is Professor of Allergy and Respiratory Medicine at the University of Santiago de Compostela, Spain and Head of the Allergy Department at the University Hospital of Santiago, Spain. She is now the Vice-president of the Spanish Society of Allergology and Clinical Immunology (SEAIC) and was the President of the Immunotherapy Committee of the SEAIC (2010-2014). Her clinical and research interests include molecular diagnosis of allergic diseases and allergen immunotherapy.
Jean Bousquet, born in 1946, is an Honorary Professor of Pulmonary Medicine at Montpellier University, France. For 13 years, he was the Director of the Inserm (Institut de la Santé et de la Recherche Médicale) laboratory “Immunopathology of Asthma” (1994-2007). He was also the coordinator of MeDALL (Mechanisms of the Development of Allergy - Framework Programme 7 (EU) - Integrated Project 2010-2014 - FP7 success story). He has chaired GINA (Global Initiative for Asthma - 1999-2000 - National Heart, Lung and Blood Institute (NIH)) and was the ARIA (Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization (WHO)) founder (1999-current).
Jean Bousquet was Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD, 2006-2013) and is co-coordinator of the Action Plan B3 of the European Innovative Partnership on Active and Healthy Ageing (EIP on AHA, Action 5: Care Pathways, Integrated Care for Chronic Diseases).
For many years, his research was focused on allergens and immunotherapy including pioneered work in sub-lingual immunotherapy. His focus was then directed towards asthma research and he performed studies involving bronchial biopsies which demonstrated inflammation in asthma. He proposed and demonstrated the concept of airways remodelling in asthma. He also examined the relationships between asthma and rhinitis as a co-morbidity, particularly in severe patients. He has now turned his research interest to systems biology to understand the mechanisms of allergy and chronic diseases and has proposed a new definition for IgE-mediated diseases (MeDALL).
Jean Bousquet has public health interest, in particular as the chairman of the WHO GARD. The main activity of GARD was to help implementing chronic respiratory disease programmes at national (e.g. China, Italy, Kyrgystan, Turkey) or regional (Minais Gerais, Brazil) levels and in the UN Resolution A/RES/64/265. He is currently leading the Région Languedoc-Roussillon-Midi-Pyrénées programme on chronic diseases for an active and healthy ageing (Reference Site of the European Innovative Partnership on Active and Healthy Ageing).
Jean Bousquet has always combined his research, clinical and public health interests. He performed translational research from a clinical observation in his clinic to the assessment of the disease burden (epidemiology), the understanding of the mechanisms and the implementation of the results to populations developing guidelines, national or international programmes with WHO.
Jean Bousquet has edited and authored 10 books including one allergy textbook, and over 900 peer-reviewed papers posted in Pubmed. He has over 1,150 papers listed in Research Gate. He has published 4 of the 20 most cited papers in asthma. His Hirsch (H) factor is 112. He was listed as one of the 400 most cited authors in biomedical science (Scopus 1996-2011).
He was the editor of the European Respiratory Review and of Allergy (second ranking journal in the field, 2003-2009, IF: 6.2). He is currently the editor of Clinical Translational Allergy and is or has been the associate editor of over 10 journals (IF: 3.8). Among the many awards, Jean Bousquet is Doctor Honoris Causa of the University 1 of Moscow, Modena and Warsaw.